Investment Rating - The report maintains a "Buy" rating for the companies discussed, including recommendations for specific stocks such as Eft-U and Changsheng Bearings [9][10][25]. Core Insights - The report highlights the ongoing competition between GPGPU and ASIC in the chip industry, noting that while ASICs excel in low-precision tasks with better power efficiency, they still struggle to match GPGPU performance in high-precision applications [22]. - The emergence of AI applications is driving demand for AI inference, with major companies investing in self-developed AI chips to meet this growing need [22]. - The report discusses the recent advancements in brain-machine interface technology, emphasizing the establishment of pricing guidelines by the National Healthcare Security Administration to support the clinical application of these technologies [7][8][24]. Summary by Sections Macro Strategy - Recent U.S. economic data presents mixed signals, with non-farm employment slightly below expectations, alleviating some recession fears [12]. - The "tight fiscal" approach from the Trump administration is impacting market sentiment, leading to declines in U.S. stocks and the dollar [12][17]. Fixed Income - The report discusses the upcoming issuance of Haohan Convertible Bonds, with an expected listing price range of 118.73 to 132.27 yuan [20]. Industry Analysis - The competition between GPGPU and ASIC is analyzed, with GPGPU maintaining a strong market position due to superior interconnect capabilities [22]. - Major companies are increasingly investing in self-developed AI chips, with significant R&D expenditures required to cover initial costs [22]. - The report identifies key players in the AI chip manufacturing space, including Broadcom and Marvell, highlighting their competitive advantages [22]. Medical and Biological Industry - The successful implementation of brain-machine interface technology is noted, with new pricing projects established to facilitate its clinical use [7][8][24]. - The report suggests potential investment opportunities in companies involved in brain-machine interface technologies, both listed and unlisted [24].